Explore the NACFC Mobile App Menu
  • Plenary Session I: Thursday, October 18, 2018

    "Improving Outcomes of Infections in the Age of CFTR Modulators"

    Speaker: Lisa Saiman, M.D., M.P.H.

    In this session, Dr. Lisa Saiman will address the challenges of infections in people with CF and discuss why infections remain a major focus of the CF community, even in the era of effective CFTR modulators. She will provide an overview of CF infections, describe ongoing studies to increase our understanding of CF microorganisms and their optimal treatment, and discuss current strategies to develop new anti-infective agents to treat even the most difficult infections.

     

    Topics: Health Outcomes, Treatment, CFTR, Plenary, Clinical Research
  • Plenary Session II: Friday, October 19, 2018

    "Anti-inflammatories & Mucociliary Clearance Therapies in the Age of CFTR Modulators"

    Speaker: Felix Ratjen, M.D., Ph.D.

    This plenary will review the effect of CFTR dysfunction and CFTR restoration on both inflammation and mucociliary clearance in individuals with CF. Current and future therapeutic strategies to address inflammation and mucociliary clearance will be discussed, as well as how these strategies have potential to benefit both those patients using CFTR modulators and those not eligible for modulators.

    Topics: Health Outcomes, Treatment, CFTR, Plenary, Clinical Research
  • Plenary Session I: Thursday, November 2, 2017

    "Matching Medicines With Mutations"

    Speakers:   Michael P. Boyle, M.D., FCCP and Philip J. Thomas, Ph.D.

    Increasing numbers of people with CF now benefit from disease-altering small molecule therapies that target the basic defect in CFTR.  Use of these therapies has been extended recently using a combination of in vitro laboratory experiments to identify responsive mutations, and clinical trials to determine effect on clinical outcomes. This plenary will summarize how recent advances may allow in the near future over 90% of individuals with CF to benefit from therapies that target the basic defect in CFTR, including even those with the rarest disease causing mutations.

    Topics: Health Outcomes, Treatment, CFTR, Plenary, Clinical Research, Drug Development Pipeline
  • Plenary Session II: Friday, November 3, 2017

    "Lung Transplantation: Challenges & Opportunities for Advanced CF Lung Disease"

    Speakers:  Joseph Pilewski, M.D.

    Plenary 2 will review the progression of CF lung disease and the option of lung transplant to treat advanced disease. The presentation will highlight the challenges associated with each phase of the transplant journey, including the referral to a transplant center, waiting for a transplant, undergoing the transplant procedure, and the care requirements and life after transplant.  

    Topics: Clinical Trials, Plenary, Clinical Research, Drug Development Pipeline
  • Plenary Session II: Friday, October 28, 2016

    "Clinical Research: A Worldwide CF Community Effort"

    Speakers: Christiane De Boeck, M.D., Ph.D. and Patrick Flume, M.D.

    The cystic fibrosis clinical trial pipeline is at present very busy -- and this is great news. This session explains how worldwide collaboration and streamlining can optimize the efficiency in the clinical trial arena.

    Topics: Clinical Trials, Plenary, Clinical Research
  • Plenary Session I: Thursday, October 8, 2015

    "Personalized Medicine"

    Speaker: John Paul Clancy, M.D.

    This session discusses the concept of personalized medicine in cystic fibrosis, including how therapies are currently personalized and how new medications and tools will allow us to personalize therapy in a precise way.

    Topics: Personalized Medicine, Plenary, Clinical Research
Showing 1–6 of 7 results